ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/23/19

3Q19 total revenues of $1,263.1 million, a 23 percent increase over 3Q18 and a 23 percent volume increase 3Q19 GAAP diluted EPS of $2.08; non-GAAP diluted EPS of $2.79 Received 2 recent regulatory approvals - ULTOMIRIS ® (ravulizumab-cwvz) for atypical hemolytic uremic ...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

Investment Thesis The shares of Ra Pharmaceuticals ( RARX ) more than doubled in value this month following a merger agreement with UCB SA ( UCBJF ), which valued the company at ~$2.1B. Ra’s potentially blockbuster therapy Zilucoplan is undergoing a pivotal phase 03 trial for the tr...

Eidos Therapeutics (NASDAQ: EIDX)  has escaped being swallowed up by its parent company,  BridgeBio Pharma (NASDAQ: BBIO) . BridgeBio owned 54.5% of Eidos when the latter went public in June 2018; that number grew to 61% by the end of 2018 and has reached 66% today. Thus, the two ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) says the U.S. Food and Drug Administration approved its Ultomiris treatment for a second rare blood disorder. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved ULTOMIRIS ® (ravuliz...

Wednesday was a downbeat day on Wall Street, as investors continued to waver in their confidence about the likely direction of trade negotiations between the U.S. and China. After feeling more optimistic earlier in the week, market participants focused on some of the potential problems if trade ...

Investment Thesis Backed by strong pricing power, Alexion Pharmaceuticals, Inc. ( ALXN ), a biopharmaceutical company focused on rare and ultra-rare disorders, has witnessed a solid sales growth over the years. As the Big Pharma, under pressure from the generics, is slowly turning its atte...

Shares of the clinical-stage biotech   Achillion Pharmaceuticals (NASDAQ: ACHN) rose by a jaw-dropping 82% on heavy volume in pre-market trading this morning. The spark? Achillion's shares bolted higher this morning in response to a $930 million all-cash buyout offer from the rare-dise...

Alexion Pharmaceuticals (NASDAQ: ALXN ) has agreed to acquire Achillion Pharmaceuticals (NASDAQ: ACHN ) for $6.30 per share in cash for a total of ~$930M, including Achillion's cash on hand of ~$230M. More news on: Alexion Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Healthcar...